Precise modulation of ion channels for inflammation and fibrosis
SAN903 is a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCa3.1. It is currently in preclinical development for the treatment of rare inflammatory and fibrotic disorders.
How SAN903 works
IMMUNE CELLS & FIBROBLASTS
NO cytokine/collagen production
NO cell division and migration
The calcium-activated potassium ion channel, KCa3.1, is important for activation of immune cells in the brain and other tissues, and it is also involved in the abnormal production of connective tissue that can lead to fibrosis in chronic diseases. Saniona leveraged its ion channel drug discovery engine to precisely target KCa3.1, resulting in a so-called “weak activation” that has been shown in preclinical models to produce efficacy without the side effects of so-called “strong activation.”
SAN903 is expected to enter the clinic in the first half of 2022.